Вы находитесь на странице: 1из 3


1. Ilmu Penyakit Kulit dan Kelamin FK UI Hal.213

2. Nestle FO, Kaplan DH, Barker J. Mechanism of disease psoriasis. N Eng J Med [Internet].
2009. [cited 2015 Jan 24]; 361: 496-509. Available from:
3. Gudjonsson JE, Elder JT. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA,
Paller AS, Leff ell DJ, editors. Fitzpatricks dermatology in general medicine. 7th ed. United
States of America: McGraw Hill; 2008: 169-93.
4. Stern RS. Psoralen and ultraviolet A light therapy for psoriasis. N Eng J Med [Internet]. 2007
[cited 2015 Jan 24]; 357: 682-90. Available from:
5.Krueger GG. Psoriasis therapy-observational or rational? N Eng J Med [Internet]. 1993 Jun
24 [cited 2015 Jan 24]; 328(25): 1845-6. Available from
http://www.nejm.org/doi/pdf/10.1056/ NEJM199306243282511
6. Ilmu Penyakit Kulit dan Kelamin FK UI Hal.214
7. Whan B. Kim, Dana Jerome, Jensen Yeung. Diagnosis and management of psoriasis. Vol
63: April 2017. Can Fam Physician 2017;63: 278-85
8.AFSHAR M, MARTINEZ AD, GALLO RL et al.: Induction and exacerbation of psoriasis
with interferon- therapy for hepatitis C: a review and analysis of 36 cases. J Eur Acad
Dermatol Venereol 2013; 27: 771-8
9.W. Alwan, F.O. Nestle. Pathogenesis and treatment of psoriasis: exploiting
pathophysiological pathways for precision medicine . Clin Exp Rheumatol 2015; 33 (Suppl.
93): S2-S6.
10.Huang X, Tanojo H, Lenn J, Deng CH, Krochmal L. A novel foam vehicle for delivery of
topical corticosteroids. J Am Acad Dermatol. 2005;53(1 suppl 1):S26-S38.
11.National Psoriasis Foundation (NPF). Topical steroids potency chart.
Accessed January 9, 2016.
12.Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: An updated
practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol.
2004;93(3 suppl 2):S1-S21
13.Boguniewicz M. Topical treatment of atopic dermatitis. Immunol Allergy Clin North Am.
2004;24(4):631-644, vi-vii.
14.Leung DY, Nicklas RA, Li JT, et al. Disease management of atopic dermatitis: An updated
practice parameter. Joint Task Force on Practice Parameters. Ann Allergy Asthma Immunol.
2004;93(3 suppl 2):S1-S21.
15.Castela E, Archier E, Devaux S, et al. Topical corticosteroids in plaque psoriasis: A
systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol.
2012;26(suppl 3):36-46. 22.
16.Levin E, Gupta R, Butler D, Chiang C, Koo JY. Topical steroid risk analysis: Differentiating
between physiologic and pathologic adrenal suppression. J Dermatolog Treat. 2014;25(6):501-
17.Chi CC, Mayon-White RT, Wojnarowska FT. Safety of topical corticosteroids in
pregnancy: A population-based cohort study. J Invest Dermatol. 2011;131(4):884-891.
18.Menter A, Cram DL. The Goeckerman regimen in two psoriasis day care centers. J Am
Acad Dermatol. 1983;9(1):59-65
19.Bagel J. LCD plus NB-UVB reduces time to improvement of psoriasis vs. NB-UVB alone.
J Drugs Dermatol. 2009;8(4):351-357.
20.McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ. The anti-
psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial
membrane potential, and induces apoptosis through a pathway dependent on respiratory
competent mitochondria. FASEB J. 2005;19(8):1012-1014.
21.Stern RS: Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med.
2007;357(7):68290. 10.1056/NEJMct072317 [PubMed] [Cross Ref]
22.Hnigsmann H: Phototherapy for psoriasis. Clin Exp Dermatol. 2001;26(4):34350.
10.1046/j.1365-2230.2001.00828.x [PubMed] [Cross Ref]
23.Danno K, Toda K, Horio T: Ultraviolet-B radiation suppresses mast cell degranulation
induced by compound 48/80. J Invest Dermatol. 1986;87(6):7758
24.Bagel J: Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of
moderate to severe psoriasis. J Drugs Dermatol. 2011;10(4):36671. [PubMed]
25.Wolf P, Hofer A, Weger W, et al. : 311 nm ultraviolet B-accelerated response of psoriatic
lesions in adalimumab-treated patients. Photodermatol Photoimmunol Photomed.
2011;27(4):1869. 10.1111/j.1600-0781.2011.00594.x [PubMed] [Cross Ref]
26.Sivamani RK, Correa G, Ono Y, Bowen MP, Raychaudhuri SP, Maverakis E.
BIOLOGICAL THERAPY OF PSORIASIS. Indian Journal of Dermatology. 2010;55(2):161-
170. doi:10.4103/0019-5154.62754.
27.M.D Colombo, N. Cassano, G.Bella and G. A. Vena. Cyclosporine Regimens in Plaque
Psoriasis: An Overview with Special Emphasis on Dose, Duration, and Old and New Treatment
Approches. Volume 2013, Article ID 805705, 11 pages.
28.Stef P. MENTING, Paul M. DEKKER, Jacqueline LIMPENS,Lotty HOOFT and Phyllis I.
SPULS. Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the
Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic
Acid Supplementation. Acta Derm Venereol 2016; 96: 2328.
29.Rashmi Sarkar, Shikha Chugh, Vijay K Garg. Acitretin in dermatology2013. 79 Issue 6,
759-771. Department of Dermatology, Maulana Azad Medical College, New Delhi, India
30. Ilmu penyakit kulit dan kelamin FK UI. Edisi ketujuh. Hal 217-218
31. Nestle FO, Kaplan DH, Barker J: Psoriasis. N Engl J Med 2009; 361: 496-509.